EVO vs ANIP
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
EVO · Evotec$1.69 ▼ 4.79%
ANIP · ANI Pharmaceuticals$67.41 ▼ 3.17%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- EVO -43.5%
- ANIP -24.2%
Head to head
| Metric | EVO | ANIP |
|---|---|---|
| Price | $1.69 | $67.41 |
| Change today | ▼ 4.79% | ▼ 3.17% |
| Market cap | $600.61M | $1.53B |
| Return, 3 months | -18.8% | -11.0% |
| Return, year to date | -45.1% | -14.6% |
| Return, 1 year | -45.1% | -25.5% |
| P/E (TTM) | -3.0 | 13.4 |
| P/B | 0.8 | 2.4 |
| P/E percentile vs own 5y | 78th | 62nd |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -16.2% | +25.9% |
| Net profit growth (YoY) | -7.3% | +189.1% |
| Gross margin | 8.5% | 60.4% |
| Operating margin | -20.0% | 13.3% |
| Net margin | -27.5% | 10.2% |
| Return on equity | -26.1% | 19.3% |
| Analyst target vs. price | +136.7% | +55.6% |
| Analyst buy share | 100% | 71% |
| RSI (14) | 58 | 35 |
| 30-day volatility | 68.0% | 27.8% |
| Max drawdown, 1 year | -67.5% | -28.7% |
| Trend read | Leaning bullish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ANIP is the largest of the group by market value.
- ANIP has returned the most over the past year.
- EVO carries the lowest trailing P/E.
- ANIP is growing revenue fastest.
- ANIP keeps the most profit per dollar of sales.
- ANIP has been the calmest stock over the last 30 days.